Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WEF-001 in Advanced KRAS-Mutant Solid Tumours
2024-518644-21-01Phase 2Authorised
- Sponsor
- Auricula Biosciences Inc.
- Start
- Dec 2025
- Modality
- Albumin → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of WEF-001 in pancreatic adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more, sponsored by Auricula Biosciences Inc. Primary endpoints: Phase 1 safety and tolerability, Phase 1 dose modifications and 2 more. Planned start Dec 2025; status: authorised.
02
Drugs
WEF-001
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)Serous Papillary Cystadenocarcinomacholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-518644-21-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518644-21-01.